Grant received in 2022
DCCC has funded 200,000 DKK to the project
Early stage bladder cancer is treated with mitomycin C (MMC), when the patients has a low risk of progression to muscle invasive disease, and with Bacillus Calmette-Guerin (BCG), when the risk of progression is high. We have developed a molecular tumor classification system for predicting risk of progression based on the molecular characteristics (Nature Com, 2021). In addition, we have found that circulating tumor DNA in early stage bladder cancer is associated with high risk disease (Eur Urol, 2016).
We apply for funding to prepare an investigator initiated multicenter national study aiming at:
- investigating the effect of escalated treatment (BCG) to patients with clinical low risk NMIBC, where the molecular profile
indicates high risk - investigating the effect of escalated treatment (BCG+checkpoint inhibitors) to patients with clinical high risk NMIBC, AND with a
molecular profile that indicates high risk based on tumor and ctDNA measurements.
Multidisciplinary organisation
DMCG Danish Bladder Cancer Group og DCCC Danish Research Centre for circulating tumor DNA guided treatment
Project stakeholder
Molecular analysis will be performed by:
- Lars Dyrskjøt Andersen, professor, PhD, Aarhus University, and the Department of Molecular Medicine (MOMA), Aarhus University Hospital, and co-chair of the National Research Center DCCC ctDNA. Primary contact lars@clin.au.dk
- Associate Professor, PhD, Karin Birkenkamp-Demtröder
Involved Departments of Urology
- Department of Urology, Aarhus University Hospital, Professor, DMSc, Jørgen Bjerggaard Jensen, MD
- Department of Urology, Gødstrup Hospital, Gødstrup, Professor, DMSc, Jørgen Bjerggaard Jensen, MD
- Department of Urology, Herlev Hospital, Consultant Gitte Wrist Lam, MD
- Department of Urology, Aalborg University Hospital, Consultant Knud Fabrin, MD
- Department of Urology, Odense University Hospital, Consultant Thor Knak Jensen, MD
- Department of Urology, Rigshospitalet, Consultant, PhD Ulla Joensen, MD
- Department of Urology, Zealand University Hospital, Consultant, PhD Juan Vasquez, MD
Oncological treatments are performed in collaboration with:
- Department of Oncology, Aarhus University Hospital, Consultant Mads Agerbæk, MD
- Department of Oncology, Herlev Hospital, Consultant, PhD Line Hammer Dohn, MD
- Department of Oncology, Aalborg University Hospital, Consultant, PhD Andreas Carus, MD
- Department of Oncology, Rigshospitalet, Consultant Helle Pappot, MD
- Department of Oncology, Odense University Hospital, Consultant Niels Viggo Jensen, MD